Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072722
Status:
COMPLETED
Last Update Posted:
2006-12-19
First Post:
2003-11-07
Brief Title:
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer HRPC
Sponsor:
Celgene Corporation
Organization:
Celgene
Study Overview
Official Title:
Phase II Randomized Open-Label Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer HRPC
Status:
COMPLETED
Status Verified Date:
2006-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II randomized open-label two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer HRPC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None